Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma

Journal of Surgical Oncology

Volumn 102, Issue 5, 2010, Pages 490-496

  Masuda, Toshiro ^a   Beppu, Toru ^a   Horino, Kei ^a   Komori, Hiroyuki ^a   Hayashi, Hiromitsu ^a   Okabe, Hirohisa ^a   Otao, Ryu ^a   Horlad, Hasita ^a   Ishiko, Takatoshi ^a   Takamori, Hiroshi ^a   Kikuchi, Ken ^b   Baba, Hideo ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Alpha fetoprotein (AFP); Doubling time; Hepatocellular carcinoma (HCC); Protein induced by vitamin K absence (PIVKA II); Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; PROTEIN INDUCED BY VITAMIN K ABSENCE; TUMOR MARKER; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; PROTEIN PRECURSOR; PROTHROMBIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PREDICTION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; BLOOD; CARCINOMA, HEPATOCELLULAR; FOLLOW UP; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL RATE; TIME; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PROTHROMBIN; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77957364703     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21451     Document Type: Article

References (43)

1. Poon RT: Optimal initial treatment for early hepatocellular carcinoma in patients with preserved liver function: Transplantation or resection? Ann Surg Oncol 2007;14:541-547.
2. Sasaki Y, Yamada T, Tanaka H, et al.: Risk of recurrence in a long-term follow-up after surgery in 417 patients with hepatitis B- or hepatitis C-related hepatocellular carcinoma. Ann Surg 2006;244:771-780. (Pubitemid 44629952)
3. Ercolani G, Grazi GL, Ravaioli M, et al.: Liver resection for hepatocellular carcinoma on cirrhosis: Univariate and multivariate analysis of risk factors for intrahepatic recurrence. Ann Surg 2003;237:536-543. (Pubitemid 38176435)
4. Nagasue N, Ono T, Yamanoi A, et al.: Prognostic factors and survival after hepatic resection for hepatocellular carcinoma without cirrhosis. Br J Surg 2001;88:515-522.
5. Adachi E, Maehara S, Tsujita E, et al.: Clinicopathologic risk factors for recurrence after a curative hepatic resection for hepatocellular carcinoma. Surgery 2002;131:S148-S152.
6. Hanazaki K, Kajikawa S, Koide N, et al.: Prognostic factors after hepatic resection for hepatocellular carcinoma with hepatitis C viral infection: Univariate and multivariate analysis. Am J Gastroenterol 2001;96:1243-1250.
7. Park JH, Koh KC, Choi MS, et al.: Analysis of risk factors associated with early multinodular recurrences after hepatic resection for hepatocellular carcinoma. Am J Surg 2006;192:29-33.
8. Yeh CN, Chen MF, Lee WC, et al.: Prognostic factors of hepatic resection for hepatocellular carcinoma with cirrhosis: Univariate and multivariate analysis. J Surg Oncol 2002;81:195-202. (Pubitemid 35397151)
9. Laurent C, Blanc JF, Nobili S, et al.: Prognostic factors and longterm survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg 2005;201:656-662. (Pubitemid 41539756)
10. Yamanaka J, Yamanaka N, Nakasho K, et al.: Clinicopathologic analysis of stage II-III hepatocellular carcinoma showing early massive recurrence after liver resection. J Gastroenterol Hepatol 2000;15:1192-1198.
11. Poon RT, Fan ST, Ng IO, et al.: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. Cancer 2000;89:500-507. (Pubitemid 30640096)
12. Cucchetti A, Vivarelli M, Piscaglia F, et al.: Tumor doubling time predicts recurrence after surgery and describes the histological pattern of hepatocellular carcinoma on cirrhosis. J Hepatol 2005;43:310-316. (Pubitemid 40956885)
13. Shirabe K, Takenaka K, Gion T, et al.: Significance of alpha-fetoprotein levels for detection of early recurrence of hepatocellular carcinoma after hepatic resection. J Surg Oncol 1997;64:143-146. (Pubitemid 27106718)
14. Li JQ, Zhang YQ, Zhang WZ, et al.: Randomized study of chemoembolization as an adjuvant therapy for primary liver carcinoma after hepatectomy. J Cancer Res Clin Oncol 1995;121: 364-366.
15. Izumi R, Shimizu K, Iyobe T, et al.: Postoperative adjuvant hepatic arterial infusion of Lipiodol containing anticancer drugs in patients with hepatocellular carcinoma. Hepatology 1994;20:295-301. (Pubitemid 24233352)
16. Sun HC, Tang ZY, Wang L, et al.: Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: A randomized clinical trial. J Cancer Res Clin Oncol 2006;132:458-465. (Pubitemid 43747394)
17. Lo CM, Liu CL, Chan SC, et al.: A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007;245:831-842.
18. Takayama T, Sekine T, Makuuchi M, et al.: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trial. Lancet 2000;356:802-807.
19. Zhou L, Liu J, Luo F: Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006;12:1175-1181.
20. Daniele B, Bencivenga A, Megna AS, et al.: Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology 2004;127:S108-112.
21. Nagaoka S, Yatsuhashi H, Hamada H, et al.: The des-gammacarboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma. Cancer 2003;98:2671-2677.
22. Toyoda H, Kumada T, Kiriyama S, et al.: Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006;4:111-117.
23. Koike Y, Shiratori Y, Sato S, et al.: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: A prospective analysis of 227 patients. Cancer 2001;91:561-569.
24. Taouli B, Goh JS, Lu Y, et al.: Growth rate of hepatocellular carcinoma: Evaluation with serial computed tomography or magnetic resonance imaging. J Comput Assist Tomogr 2005;29:425-429.
25. Kubota K, Ina H, Okada Y, et al.: Growth rate of primary single hepatocellular carcinoma: Determining optimal screening interval with contrast enhanced computed tomography. Dig Dis Sci 2003;48:581-586. (Pubitemid 36324168)
26. Ikai I, Arii S, Kojiro M, et al.: Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 2004;101:796-802. (Pubitemid 39030937)
27. Ha-Kawa SK, Tanaka Y, Hasebe S, et al.: Compartmental analysis of asialoglycoprotein receptor scintigraphy for quantitative measurement of liver function: A multicentre study. Eur J Nucl Med 1997;24:130-137. (Pubitemid 27121091)
28. Farinati F, Marino D, De Giorgio M, et al.: Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: Both or neither? Am J Gastroenterol 2006;101:524-532. (Pubitemid 43340928)
29. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, et al.: Clinical characteristics and prognosis of hepatocellular carcinoma: Analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000;31:302-308.
30. Minagawa M, Ikai I, Matsuyama Y, et al.: Staging of hepatocellular carcinoma: Assessment of the Japanese TNM and AJCC/UICC TNM systems in a cohort of 13,772 patients in Japan. Ann Surg 2007;245:909-922. (Pubitemid 46809293)
31. Sheu JC, Sung JL, Chen DS, et al.: Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985;89:259-266. (Pubitemid 15028580)
32. Koga H, Moriya Y, Akasu T, et al.: The relationship between prognosis and CEA-dt after hepatic resection in patients with colorectal carcinomas. Eur J Surg Oncol 1999;25:292-296. (Pubitemid 29261291)
33. Nishida K, Kaneko T, Yoneda M, et al.: Doubling time of serum CA 19-9 in the clinical course of patients with pancreatic cancer and its significant association with prognosis. J Surg Oncol 1999;71:140-146. (Pubitemid 29340776)
34. Chevret S, Trinchet JC, Mathieu D, et al.: A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. J Hepatol 1999;31:133-141.
35. Fujioka M, Nakashima Y, Nakashima O, et al.: Immunohistologic study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology 2001;34:1128-1134. (Pubitemid 33096585)
36. Yano Y, Yamashita F, Kuwaki K, et al.: Clinical features of hepatitis C virus-related hepatocellular carcinoma and their association with alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II. Liver Int 2006;26:789-795. (Pubitemid 44165246)
37. Kumada T, Nakano S, Takeda I, et al.: Clinical utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: Special reference to imaging diagnosis. J Hepatol 1999;30:125-130. (Pubitemid 29023661)
38. Williams R, Melia WM, Johnson PJ: Serum alpha-foetoprotein in hepatocellular carcinoma - Value in diagnosis, and prognosis. Ann Acad Med Singapore 1980;9:245-250. (Pubitemid 11177569)
39. Johnson PJ, Williams R: Serum alpha-fetoprotein estimations and doubling time in hepatocellular carcinoma: Influence of therapy and possible value in early detection. J Natl Cancer Inst 1980;64:1329-1332.
40. Shirabe K, Itoh S, Yoshizumi T, et al.: The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007;95:235-240.
41. Soejima Y, Taketomi A, Yoshizumi T, et al.: Extended indication for living donor liver transplantation in patients with hepatocellular carcinoma. Transplantation 2007;83:893-899. (Pubitemid 46682729)
42. Takada Y, Ito T, Ueda M, et al.: Living donor liver transplantation for patients with HCC exceeding the Milan criteria: A proposal of expanded criteria. Dig Dis 2007;25:299-302. (Pubitemid 350014956)
43. Rodriguez-Diaz JL, Rosas-Camargo V, Vega-Vega O, et al.: Clinical and pathological factors associated with the development of hepatocellular carcinoma in patients with hepatitis virus-related cirrhosis: A long-term follow-up study. Clin Oncol (R Coll Radiol) 2007;19:197-203. (Pubitemid 46268576)